

SCIENTIFIC REPORT

VISION HEALTH RESEARCH NETWORK

INSTRUCTIONS

**Deadline to submit a report:**

* At the end of each grant and if no renewal application is requested, a final report must be submitted to the VHRN (in the case of a renewal, the scientific report – progress report - is **included** in the application form)
* An update may be requested for the VHRN renewal

**No member of the VHRN shall be eligible to apply for fundings (all competitions combined) if they are not up to date with the reports requested by the Network for grants on which they were listed as researcher or co-researcher.**

**Please send your report to**:
Vision Health Research Network
reseau.vision@ircm.qc.ca

**For additional information, please contact:**Vision Health Research Network

514-987-5636

visionnetwork.ca



**SCIENTIFIC REPORT**

**VISION HEALTH RESEARCH NETWORK**

**FORM**

**PERIOD COVERED BY THE REPORT**

|  |  |  |
| --- | --- | --- |
| Check | Program | Years covered by the report |
|  | Common Infrastructures (IF) | December 2018 – September 2020 (VHRN renewal period)End of the grant (year / month):  |
|  | National and International Networking (NIN) | Date of first grant (year / month): End of the grant (year / month): |
|  | Age-related Macular Degeneration (AMD)  | Date of first grant (year / month): End of the grant (year / month): |

## PROJECT TITLE:

**Researcher Program Manager** (must be a faculty member of a recognized Quebec university or a permanent member of a clinical ophthalmology unit of a university hospital.)

Last name, First name and titles:

Main affiliation:

Address:

Email:

Phone number

## IF Program: Name and contact information to whom requests to use the infrastructure data should be directed.

**Signature of the researcher responsible for the program**

As the researcher in charge of the research initiative mentioned above, I declare that the information provided in this report is exact, to the best of our knowledge;

As the researcher in charge of the research initiative mentioned above, I declare that contributors and users have been advised of their inclusion in this report.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Name** **Signature Date**

**IF PROGRAM ONLY**

**DESCRIPTION OF THE INFRASTRUCTURE** (maximum 1 page)

* Describe the infrastructure: (**1) nature and mission of the infrastructure**, **(2) type of data** or biological material, type of studied parameters, number of patients, etc.,
* Describe **(3) how this infrastructure is the managed** and describe its **(4) accessibility** to the members of the Network
* Describe the **(5) management of the ethic aspect**

**NIN / AMD PROGRAMS ONLY**

**PROJECT SUMMARY FOR LAY AUDIENCE** (in French and English)

**NIN program**: Describe in nontechnical language the purpose of the study, the expected results and the expected impact of this collaboration on the outreach of VHRN researchers at the national and / or international level

**AMD program:** Summarize in nontechnical language to a non-scientific audience your project and its meaning as well as the major results obtained and the expected impact for the patient.

*For dissemination and promotion*

**Titre du projet** :

Résumé vulgarisé du projet et signification :

Résultats majeurs :

Impact :

Conclusion :

\* \* \*

**Project title**:

Summary report and meaning:

Major results:

Impact:

Conclusion:

**USERS AND PARTICIPANTS** (add pages as needed)

**IF program**: List the names of those who have contributed to, used and/or benefited from this infrastructure between 2018 and 2022.

**NIN / AMD programs**: List the names of those who have been involved in this project

\* \* \*

1. Fill in the table with the number of users.
2. Group users according to the categories listed below. This list is expected to reflect that of authors listed in the publications permitted by the funding of this infrastructure or partnership project.

**Summary table**

|  |  |
| --- | --- |
| Categories | Number(years: \_\_\_\_\_-\_\_\_\_\_\_\_) |
| Basic research (QC researchers and collaborators) |  |
| Clinical research (QC researchers and collaborators) |  |
| National collaborators  |  |
| International collaborators |  |
| Undergraduate students |  |
| MD students and fellows |  |
| MSc students |  |
| PhD students |  |
| Postdoctoral fellows |  |
| Research assistants |  |
| Others (government agency, industry; etc.) |  |
| Total |  |

**Detailed list (names and institutions):**

## Researchers (Basic research):

## Clinician researchers and collaborators (Clinical research):

## National collaborators:

## International collaborators:

## Undergraduate students:

## MD students and fellows

## MSc students:

## PhD students:

## Postdoctoral fellows:

## Research assistants:

## Others (government agency, industry, etc.):

**SCIENTIFIC RESULTS** (maximum 2 pages)

**IF program**: Describe the scientific discoveries ensued from the use of this common infrastructure between 2018-2022.

**NIN program:** Describe the scientific discoveries generated by this project.

**AMD program:** Describe the scientific discoveries generated by this project that will help improve treatments, prevention and/or rehabilitation for people suffering from AMD.

Please make the content of your text accessible to a researcher who is not in your field.

**PERFORMANCE** (maximum 4 pages, excluding the present page)

**Do not repeat information of the scientific results section**

**Include only the information relevant to the Infrastructure, program or project**

**IF program**: Describe the relevance, strategic advantage and the impact of this infrastructure on the performance of the Network between 2018 and 2022.

**NIN program:** Describe the national and international collaborative nature of this project.

**AMD program**: Describe the impact of this research on the progress of the scientific knowledge on AMD (for the improvement of treatment, prevention and/or rehabilitation for people suffering from AMD), as well as its role in recruiting and developing a critical mass of AMD researchers in Quebec and in consolidating Quebec's place in the field of AMD research in Canada and internationally.

\* \* \*

Scientifics reports will be assessed following the FRQS performance criteria established for the evaluation of their Thematic Networks, as listed below.

**Please answer to all the items listed below when applicable.**

1. Leverage effect (grants, public or private investments, partnerships with the biopharmaceutical industry or others).
2. Specify the title of the grant, the authors, the funding agency, the dates of beginning and end, and the amounts per year.
3. Explain briefly how the Network played a role in the attribution of the grant.
4. If it is an “in kind” partnership, describe and estimate the amount
5. Development of new strategic and structuring initiatives
6. National and international visibility
7. Biotechnology development
8. Added value for VHRN members and the scientific community
9. Development of cross-sector projects and poles of excellence
10. Training of the next generation
11. Promotion of clinical research
12. Added value for target community (new treatments, new personalized health care implementation of new health practices or policies).
13. Knowledge transfer, valorization and public communications activities
14. Free access to the results
15. Highlight success stories

**PUBLICATIONS and COMMUNICATIONS** (add the number of pages required)

**IF program**: Provide a list of ALL PUBLICATIONS AND CONFERENCES that have resulted directly or indirectly from the use of this infrastructure during the last year.

**NIN / AMD program:** Provide a list of ALL PUBLICATIONS AND CONFERENCES that have resulted directly or indirectly from this partnership project.

\* \* \*

1. Group according to categories
2. Bold the names of the investigators members of the VHRN
3. **Precede by an asterix (\*) all publications where funding by the VHRN is mentioned in the Acknowledgements section.**

\*Reminder: It is essential that researchers acknowledge the VHRN and/or the *Fondation Antoine-Turmel (FAT)*, when applicable, in each publications and presentations for which funding from the VHRN or the FAT contributed (directly or indirectly). If this is has not been done, the FRQS will not recognize these articles and abstracts in its evaluation of our Network, which will reduce the passing grade and possibly the allocated funding.

|  |  |
| --- | --- |
| Summary Table | Number(years:\_\_\_\_\_\_-\_\_\_\_\_\_\_) |
| Articles in peer reviewed journals |  |
| 1 (\*). Articles in peer reviewed journals in which the VHRN was acknowledged |  |
| Book chapters |  |
|  Provincial Conferences |  |
| 3.2 National Conferences |  |
| 3.3 International Conferences |  |
| Total |  |

**Detailed list:**

1. Articles in peer reviewed journals

-

1. Book chapters

4. Oral presentations and posters

4.1. Provincial Conferences

-

-

4.2. National Conferences

-

-

4.3. International Conferences

-

-